<DOC>
	<DOCNO>NCT00001461</DOCNO>
	<brief_summary>The wall blood vessel line flat cell responsible release substance ( ) control activity blood vessel . These cell refer endothelium blood vessel . One substance release endothelium call nitric oxide ( NO ) . This substance function keep blood vessel relax prevent blood clot inside vessel . Studies do researcher Cardiology Branch National Heart , Lung Blood Institute show nitric oxide activity may lower patient harden artery ( atherosclerosis ) risk factor atherosclerosis . Another substance release cell endothelium call bradykinin . It function stimulate production nitric oxide . Therefore bradykinin also responsible relaxation widen blood vessel . An enzyme find blood call angiotensin-converting enzyme ( ACE ) inactivate baradykinin thereby decrease production nitric oxide . The activity ACE determine genetics different person . Medications block ACE ( ACE-inhibitors ) may useful patient high level ACE activity . This study design determine ; 1 . The role bradkinin stimulate production nitric oxide 2 . Whether ACE-inhibitors improve blood vessel relaxation cause bradykinin 3 . Whether ACE-inhibitors improve abnormal blood vessel relaxation 4 . Whether ACE-inhibitors bradykinin affect blood clot 5 . Whether blood vessel response ACE-inhibitor bradykinin depend patient genetic make-up</brief_summary>
	<brief_title>Study Interaction Between Cells Lining Blood Vessels Angiotensin-Converting Enzyme</brief_title>
	<detailed_description>The vascular endothelium tonically release nitric oxide produce smooth muscle relaxation , inhibition platelet aggregation , inhibition cellular proliferation . Studies Cardiology Branch demonstrate nitric oxide activity reduce coronary peripheral vasculature patient atherosclerosis risk factor atherosclerosis . Bradykinin , endothelium-dependent vasodilator , may important modulator vascular tone vivo tonically produce endothelium . Bradykinin inactivate angiotensin convert enzyme ( ACE ) find endothelial cell surface . The activity plasma ACE variable among individual least partly genetically determine . ACE activity may modulate local vascular effect bradykinin , thus , ACE inhibitor would expect improve endothelium-dependent response patient higher tissue ACE activity . This protocol design determine 1 ) role bradykinin stimulate nitric oxide release human coronary peripheral vasculature ; 2 ) whether ACE inhibitor improve bradykinin-induced vasodilation , , whether occurs result endothelium-dependent release nitric oxide ; 3 ) whether ACE inhibitor improve abnormal shear-induced coronary vasodilation patient normal coronary artery coronary artery disease ; 4 ) whether ACE inhibitor bradykinin affect platelet function ; 5 ) whether vascular response ACE inhibition bradykinin depend ACE genotype .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Anyone chest pain know suspected coronary artery disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Angiotensin Converting Enzyme</keyword>
	<keyword>Angiotensin Converting Enzyme Inhibitors</keyword>
	<keyword>Bradykinin</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>